Company news

Cingulate Inc. news in 2026

Cingulate Inc.'s news releases, calls and decks from 2026, newest first.

View company

Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma

September 17, 2026

Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

August 13, 2026

Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile

August 11, 2026

Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology

July 30, 2026

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

July 1, 2026

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301

June 16, 2026

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26

June 3, 2026

Cingulate Receives Complete Response Letter from FDA for CTx-1301

June 1, 2026

Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

May 13, 2026

Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

March 17, 2026

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

February 17, 2026

Decks in 2026